You are here: Industry Insights > BRCA-Mutated

News List

AstraZeneca announces positive results from SOLO-3 trial of Lynparza pharmaceutical-technology
December 21, 2018
AstraZeneca and its partner Merck have published positive results from SOLO-3 phase III trial of Lynparza, which is indicated for BRCA-mutated (BRCAm) advanced ovarian cancer.
Lynparza Approved by FDA for First-Line Maintenance Therapy in BRCA-Mutated Advanced Ovarian Cancer americanpharmaceuticalreview
December 20, 2018
AstraZeneca and Merck announced the US Food and Drug Administration (FDA) has approved Lynparza for the maintenance treatment of adult patients with deleterious or......
Lynparza Approved in Japan for BRCA-Mutated Metastatic Breast Cancer americanpharmaceuticalreview
July 11, 2018
AstraZeneca and Merck announced Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) has approved Lynparza (olaparib) tablets for use in patients with unresectable or recurrent BRCA-mutated (BRCAm), human epidermal growth factor receptor 2 (HER2) neg